New schizophrenia drug SEP-363856 tested for Long-Term safety in 100 patients
NCT ID NCT07225712
First seen Nov 10, 2025 · Last updated May 21, 2026 · Updated 28 times
Summary
This study is testing a new medication called SEP-363856 in 100 adults with schizophrenia who are already stable on their current treatment. The goal is to see how safe and tolerable the drug is when taken for a full year. Participants will take either 75 mg or 100 mg daily, and researchers will monitor for side effects and overall well-being.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Jimbo Kokorono Clinic
RECRUITINGFukuoka, Japan
Conditions
Explore the condition pages connected to this study.